Search

Your search keyword '"Rugge M."' showing total 1,633 results
Start Over Author "Rugge M."
1,633 results on '"Rugge M."'

2. Use of Routine Health Datasets to Assess the Appropriateness of Diagnostic Tests in the Follow-Up of Breast Cancer Patients: A Population-Based Study on 3930 Patients

Author

Gion M, Cardinali G, Guzzinati S, Morandi P, Trevisiol C, Fabricio ASC, Rugge M, and Zorzi M

Subjects
tumour markers, imaging exams, adherence to guidelines, routinely-collected health data, Public aspects of medicine, RA1-1270
Abstract

Massimo Gion,1 Giulia Cardinali,2 Stefano Guzzinati,3 Paolo Morandi,4 Chiara Trevisiol,5 Aline SC Fabricio,5 Massimo Rugge,3,6 Manuel Zorzi3 1Regional Center for Biomarkers, Department of Clinical Pathology, Azienda ULSS 3 Serenissima, Venice, Italy; 2Management Control Unit, Azienda ULSS 3 Serenissima, Venice, Italy; 3Veneto Tumour Registry, Azienda Zero, Padua, Italy; 4Medical Oncology Unit, Azienda ULSS 3 Serenissima, Venice, Italy; 5Veneto Institute of Oncology IOV - IRCCS, Padua, Italy; 6University of Padova, Department of Medicine DIMED, Padua, ItalyCorrespondence: Massimo Gion, Regional Center for Biomarkers, Department of Clinical Pathology, Azienda ULSS 3 Serenissima, Ospedale SS. Giovanni e Paolo – Castello, Venezia, 6777 – 30122, Italy, Tel +39 041 5294260, Fax +39 041 5295603, Email massimo.gion@aulss3.veneto.itPurpose: Clinical practice guidelines (CPGs) recommend against intensive follow-up in asymptomatic women with breast cancer (BC). The present study assessed the adherence to CPGs of diagnostic tests ordering during BC follow-up by exploring routinely collected health data through an algorithm developed to distinguish patients according to their status at follow-up.Patients and Methods: A retrospective population-based cohort study was performed monitoring the diagnostic tests ordered during 5 years of follow-up in all BC cases incident in 2013 in the Veneto Region, Italy. Data were extracted from the Veneto Tumour Registry, the Hospital Discharge Records and the Outpatients’ Records of Diagnostic and Therapeutic Procedures. The algorithm was developed using information on infusion of anticancer agents, imaging exams ordered, and death.Results: The algorithm classified patients by status at follow-up in four groups: (i) probably no-evidence-of-disease (NED), (ii) suspicious signs of relapse not confirmed, (iii) increased risk of relapse and (iv) advanced disease at presentation or progressive disease. A total of 3930 consecutive incident cases were followed-up for 5 years, corresponding to 17,184 person-years, 15,345 of which pertaining to NED cases. In NED cases, 32,900 tumour markers and 15,858 imaging exams were ordered. Liver ultrasonography and chest radiography were most frequently ordered.Conclusion: In contrast with recommendations of CPGs, a substantial overordering of tumour markers and imaging exams occurred in NED BC patients. The developed algorithm can be repeatedly applied to routine health datasets for regular monitoring of the adherence to CPGs and of the impact of interventions to improve appropriateness.Keywords: tumour markers, imaging exams, adherence to guidelines, routinely collected health data

Published
2022

4. Programmed cell death 4 (PDCD4) as a novel prognostic marker for papillary thyroid carcinoma

Author

Galuppini F, Fassan M, Bertazza L, Barollo S, Cascione L, Watutantrige-Fernando S, Lazzarin V, Simonato P, Vianello F, Rugge M, Mian C, and Pennelli G

Subjects
papillary thyroid cancer, PDCD4, BRAF, outcome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Francesca Galuppini,1 Matteo Fassan,1 Loris Bertazza,2 Susi Barollo,2 Luciano Cascione,3 Sara Watutantrige-Fernando,4 Vanni Lazzarin,1 Paolo Simonato,1 Federica Vianello,4 Massimo Rugge,1 Caterina Mian,2 Gianmaria Pennelli11Pathology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy; 2Endocrinology Unit, Department of Medicine (DIMED), University of Padova, Padova 35121, Italy; 3Università Della Svizzera Italiana, Institute of Oncology Research and Swiss Institute of Bioinformatics, Bellinzona 6500, Switzerland; 4Department of Radiotherapy, Istituto Oncologico del Veneto, Padova 35128, ItalyCorrespondence: Gianmaria PennelliSurgical Pathology Unit, Department of Medicine (DIMED), University of Padova, Via Aristide Gabelli, Padua 61 35121, ItalyTel +39 049 821 8996Fax +39 049 821 7655Email gianmaria.pennelli@unipd.itBackground: The primary goal of papillary thyroid cancer (PTC) management was to stratify patients at pre- and post-surgical level to identify the small proportion of cases with potentially aggressive disease.Purpose: The aim of our study is to evaluate the possible role of programmed cell death 4 (PDCD4) and BRAF status as prognostic markers in PTC.Patients and methods: We investigate programmed cell death 4 (PDCD4) immunohistochemical expression in 125 consecutive PTCs with median follow-up of 75.3 months (range, 15–98 months) to verify the possible correlation between BRAF status and correlate the classical clinicopathological prognostic factors and PTC outcome with PDCD4 expression. To further support the data, miR-21 expression was tested (by quantitative real-time PCR and in situ hybridization) in a different series of 30 cases (15 PTCs BRAFwt and 15 PTCs BRAFV600E). Moreover, we validated our results using TGCA thyroid carcinoma dataset.Results: We found that 59.8% of the patients showed low-grade PDCD4 nuclear expression and low-grade expression correlated with BRAF V600E. Compared with BRAF 15 wild-type tissue samples, a significant miR-21 up-regulation was associated with BRAF V600E mutations. Low-grade PDCD4 resulted, and was associated with aggressive histological variants, higher cancer size, extra-thyroidal extension, multifocality, lymph-node metastasis and lymph nodal ratio at the diagnosis. Concerning the outcome, the low-grade PDCD4 expression correlated at univariate and multivariate analysis, with lower levels of recurrence-free survival rate (RFS) and with poor outcome. Moreover, there was significant association between BRAF V600E patients with PDCD4 nuclear loss and lower RFS, whilet here was significant association between BRAF wild-type patients with PDCD4 nuclear expression and better outcome.Conclusion: These results showed that PDCD4 could predict PTC outcome and that the sum of PDCD4 and BRAF alterations increases the prognostic power of BRAF mutation alone.Keywords: papillary thyroid cancer, PDCD4, BRAF, outcome

Published
2019

6. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study

Author

Hackl, M., Zielonke, N., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Dušek, L., Zvolský, M., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Bouvier, A.M., Faivre, J., Bossard, N., Uhry, Z., Colonna, M., Stabenow, R., Luttmann, S., Eberle, A., Brenner, H., Nennecke, A., Engel, J., Schubert-Fritschle, G., Heidrich, J., Holleczek, B., Katalinic, A., Clough-Gorr, K., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Maso, L. Dal, De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Knijn, A., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Natali, M., Filiberti, R.A., Marani, E., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Traina, A., Staiti, R., Vitale, F., Cusimano, R., Michiara, M., Tumino, R., Falcini, F., Caiazzo, A.L., Maspero, S., Fanetti, A.C., Zanetti, R., Rosso, S., Rugge, M., Tognazzo, S., Pildava, S., Smailyte, G., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Kępska, K., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Antunes, L., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Almar, E., Mateos, A., Lopez de Munain, A., Larrañaga, N., Torrella-Ramos, A., Díaz García, J.M., Jimenez-Chillaron, R., Marcos-Gragera, R., Vilardell, L., Moreno-Iribas, C., Ardanaz, E., Lambe, M., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Damhuis, R., Otter, R., Coleman, M., Allemani, C., Rachet, B., Rashbass, J., Broggio, J., Verne, J., Gavin, A., Fitzpatrick, D., Huws, D.W., White, C., Minicozzi, Pamela, Innos, Kaire, Sánchez, Maria-José, Trama, Annalisa, Walsh, Paul M., Marcos-Gragera, Rafael, Dimitrova, Nadya, Botta, Laura, Visser, Otto, Rossi, Silvia, Tavilla, Andrea, and Sant, Milena

Published
2017
Full Text
View/download PDF

7. Geographical variability in survival of European children with central nervous system tumours

Author

Hackl, M., Zielonke, N., Oberaigner, W., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Storm, H., Engholm, G., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Faivre, J., Bossard, N., Uhry, Z., Colonna, M., Clavel, J., Lacour, B., Desandes, E., Brenner, H., Kaatsch, P., Katalinic, A., Garami, M., Jakab, Z., Comber, H., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Sutera Sardo, A., Mancuso, P., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Zucchetto, A., De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Busco, S., Filiberti, R.A., Marani, E., Ricci, P., Pascucci, C., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Usala, M., Vitale, F., Ravazzolo, B., Michiara, M., Merletti, F., Maule, M., Tumino, R., Mangone, L., Di Felice, E., Falcini, F., Iannelli, A., Sechi, O., Cesaraccio, R., Piffer, S., Madeddu, A., Tisano, F., Maspero, S., Fanetti, A.C., Candela, P., Scuderi, T., Stracci, F., Bianconi, F., Tagliabue, G., Contiero, P., Rugge, M., Guzzinati, S., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Bębenek, M., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Castro, C., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Errezola, M., Bidaurrazaga, J., Vicente Raneda, M., Díaz García, J.M., Marcos-Navarro, A.I., Marcos-Gragera, R., Izquierdo Font, A., Sanchez, M.J., Chang, D.Y.L., Navarro, C., Chirlaque, M.D., Moreno-Iribas, C., Ardanaz, E., Peris-Bonet, R., Pardo Romaguera, E., Galceran, J., Carulla, M., Lambe, M., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Aarts, M., Otter, R., Coleman, M., Allemani, C., Rachet, B., Verne, J., Stiller, C., Gavin, A., Donnelly, C., Brewster, D.H., Sánchez, M.-J., and Rutkowski, S.

Published
2017
Full Text
View/download PDF

8. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

Author

Hackl, M., Zielonke, N., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Dušek, L., Zvolský, M., Storm, H., Engholm, G., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Velten, M., Guizard, A.V., Faivre, J., Woronoff, A.S., Tretarre, B., Bossard, N., Uhry, Z., Colonna, M., Molinié, F., Bara, S., Schvartz, C., Lapôtre-Ledoux, B., Grosclaude, P., Stabenow, R., Luttmann, S., Eberle, A., Brenner, H., Nennecke, A., Engel, J., Schubert-Fritschle, G., Heidrich, J., Holleczek, B., Katalinic, A., Jónasson, J.G., Tryggvadóttir, L., Comber, H., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Sutera Sardo, A., Mazzei, A., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Zucchetto, A., De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Busco, S., Filiberti, R.A., Vercelli, M., Ricci, P., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Usala, M., Vitale, F., Ravazzolo, B., Michiara, M., Tumino, R., Mangone, L., Vicentini, M., Falcini, F., Iannelli, A., Sechi, O., Cesaraccio, R., Piffer, S., Madeddu, A., Tisano, F., Maspero, S., Fanetti, A.C., Zanetti, R., Rosso, S., Candela, P., Scuderi, T., Stracci, F., Rocca, A., Tagliabue, G., Contiero, P., Rugge, M., Tognazzo, S., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Bębenek, M., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Castro, C., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Errezola, M., Bidaurrazaga, J., Díaz García, J.M., Marcos-Navarro, A.I., Marcos-Gragera, R., Izquierdo Font, A., Sanchez, M.J., Molina, E., Navarro, C., Chirlaque, M.D., Moreno-Iribas, C., Ardanaz, E., Galceran, J., Carulla, M., Lambe, M., Khan, S., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Ho, V., Otter, R., Coleman, M., Allemani, C., Rachet, B., Rashbass, J., Broggio, J., Verne, J., Gavin, A., Donnelly, C., Brewster, D.H., Huws, D.W., White, C., Dal Maso, L., Pacini, F., van Dijk, B.A.C., Larrañaga, N., Rubió-Casadevall, J., Kowalska, A., and Virdone, S.

Published
2017
Full Text
View/download PDF

9. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study

Author

Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., Huws D. W., Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., and Huws D. W.

Abstract

Background: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. Methods: In this population-based study, we analysed 135 847 children (aged 0–14 years) diagnosed during 2000–13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries. We calculated age-adjusted 5-year survival differences by country and over time using period analysis, for all cancers combined and for major cancer types. We applied a variant of standard mixture cure models for survival data to estimate the cure fraction of patients by childhood cancer and to estimate projected 15-year survival. Findings: 5-year survival for all childhood cancer combined in Europe in 2010–14 was 81% (95% CI 81–82), showing an increase of three percentage points compared with 2004–06. Significant progress over time was observed for almost all cancers. Survival remained stable for osteosarcomas, Ewing sarcoma, Burkitt lymphoma, non-Hodgkin lymphomas, and rhabdomyoscarcomas. For all cancers combined, inequalities still persisted among European countries (with age-adjusted 5-year survival ranging from 71% [95% CI 60–79] to 87% [77–93]). The 15-year survival projection for all patients with childhood cancer diagnosed in 2010–13 was 78%. We estimated the yearly long-term mortality rate due to causes other than the diagnosed cancer to be around 2 per 1000 patients for all childhood cancer combined, but to approach zero for retinoblastoma. The cure fraction for patients with childhood cancer increased over time from 74% (95% CI 73–75) in 1998–

Published
2022

10. Organ donation from patients with a rare disease is often safe: the italian guidelines

Author

Dallapiccola, B, Moriconi, S, Rugge, M, Cardillo, M, Carcassi, C, Colledan, M, Strologo, L, Vici, C, Facchin, P, Gridelli, B, La Rocca, V, Lombardini, L, Mazzucato, M, Peritore, D, Amoroso, A, Dallapiccola B., Moriconi S., Rugge M., Cardillo M., Carcassi C., Colledan M., Strologo L. D., Vici C. D., Facchin P., Gridelli B., La Rocca V., Lombardini L., Mazzucato M., Peritore D., Amoroso A., Dallapiccola, B, Moriconi, S, Rugge, M, Cardillo, M, Carcassi, C, Colledan, M, Strologo, L, Vici, C, Facchin, P, Gridelli, B, La Rocca, V, Lombardini, L, Mazzucato, M, Peritore, D, Amoroso, A, Dallapiccola B., Moriconi S., Rugge M., Cardillo M., Carcassi C., Colledan M., Strologo L. D., Vici C. D., Facchin P., Gridelli B., La Rocca V., Lombardini L., Mazzucato M., Peritore D., and Amoroso A.

Abstract

Although a disease is defined as rare when it has a prevalence of less than 1:2000, the overall prevalence of rare diseases in the population is greater than 1%. Among potential organ donors, a similar frequency is observed. To date, guidelines have not been established, and operational decisions have been made empirically, case- by-case, based on the experience and expertise of clinicians. For this reason, the Italian Superior Health Council (CSS) has appointed a working Group to address “patients with a rare disease as potential organ donors,” with the aim of devising recommendations for the management of transplant cases in which the donors have a rare disease. This group evaluated 493 diseases (10% of all rare diseases, including over 95% of patients with a rare disease) to deliver a technical report dealing with the suitability of organ donation and transplantation, with a focus on the organs most frequently used, including kidney, liver, heart, lung, and pancreas. This work has made it clear that a rare disease “per se” does not contraindicate organ donation at all. Indeed, in donors affected by a rare disease, almost 80% of the organs are suitable for transplantation, approximately 7% are unsuitable, and approximately 14% are suitable as non-standard with an acceptable risk.

Published
2022

11. OC.15.2 SMALL BOWEL CARCINOMAS MAY COMPLICATE COELIAC DISEASE DESPITE STRICT ADHERENCE TO GLUTEN-FREE DIET: A CASE SERIES FROM THE SMALL BOWEL CANCER ITALIAN CONSORTIUM

Author

Bianchi, P.I., primary, Vanoli, A., additional, Lenti, M., additional, Guerini, C., additional, Arpa, G., additional, Quaquarini, E., additional, Aronico, N., additional, Grillo, F., additional, Nesi, G., additional, Furlan, D., additional, Latella, G., additional, Sessa, F., additional, Mescoli, C., additional, Rugge, M., additional, Ferrero, S., additional, Macciomei, M., additional, Santini, D., additional, Volta, U., additional, De Giorgio, R., additional, Caio, G., additional, Calabro, A., additional, Ciacci, C., additional, D'Armiento, M., additional, Villanacci, V., additional, Cannizzaro, R., additional, Canzonieri, V., additional, Florena, A., additional, Ciardi, A., additional, Elli, L., additional, Vecchi, M., additional, Zingone, F., additional, Reggiani Bonetti, L., additional, Astegiano, M., additional, Sandri, G., additional, Silano, M., additional, Usai, P., additional, Perfetti, V., additional, Giannone, A., additional, Barresi, V., additional, Ciccocioppo, R., additional, Biletta, E., additional, Corazza, G., additional, and Di Sabatino, A., additional

Published
2023
Full Text
View/download PDF

12. PC.01.9 HYPOMETHYLATION OF LINE-1 IN SMALL BOWEL CARCINOMAS AND COELIAC DISEASE

Author

Guerini, C., primary, Bianchi, P.I., additional, Libera, L., additional, Vanoli, A., additional, Arpa, G., additional, Aronico, N., additional, Furlan, D., additional, Grillo, F., additional, Nesi, G., additional, Sampietro, G., additional, Ardizzone, S., additional, Fociani, P., additional, Fiocca, R., additional, Latella, G., additional, Sessa, F., additional, D'Errico, A., additional, Malvi, D., additional, Mescoli, C., additional, Rugge, M., additional, Ferrero, S., additional, Poggioli, G., additional, Rizzello, F., additional, Macciomei, M., additional, Santini, D., additional, Volta, U., additional, De Giorgio, R., additional, Caio, G., additional, Calabro, A., additional, Ciacci, C., additional, D'Armiento, M., additional, Rizzo, A., additional, Solina, G., additional, Tonelli, F., additional, Villanacci, V., additional, Cannizzaro, R., additional, Canzonieri, V., additional, Florena, A., additional, Biancone, L., additional, Monteleone, G., additional, Caronna, R., additional, Ciardi, A., additional, Elli, L., additional, Caprioli, F., additional, Vecchi, M., additional, D'Inca, R., additional, Zingone, F., additional, D'Odorico, A., additional, Oreggia, B., additional, Reggiani Bonetti, L., additional, Astegiano, M., additional, Cantoro, L., additional, Papi, C., additional, Sandri, G., additional, Silano, M., additional, Usai, P., additional, Perfetti, V., additional, Quaquarini, E., additional, Giannone, A., additional, Orlandi, A., additional, Barresi, V., additional, Ciccocioppo, R., additional, Amodeo, G., additional, Biletta, E., additional, and Di Sabatino, A., additional

Published
2023
Full Text
View/download PDF

14. Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials

Author

Vener, C., Rossi, S., Minicozzi, P., Marcos-Gragera, R., Poirel, H. A., Maynadie, M., Troussard, X., Pravettoni, G., De Angelis, R., Sant, M., Hackl, M., Van Eycken, E., Valerianova, Z., Sekerija, M., Pavlou, P., Dusek, L., Storm, H., Magi, M., Innos, K., Malila, N., Pitkaniemi, J., Velten, M., Bouvier, A. M., Jooste, V., Guizard, A. V., Launoy, G., Yonli, S. D., Woronoff, A. S., Nousbaum, J. B., Coureau, G., Monnereau, A., Baldi, I., Hammas, K., Tretarre, B., Colonna, M., Plouvier, S., D'Almeida, T., Molinie, F., Cowppli-Bony, A., Bara, S., Schvartz, C., Defossez, G., Lapotre-Ledoux, B., Grosclaude, P., Luttmann, S., Stabenow, R., Nennecke, A., Kieschke, J., Zeissig, S., Holleczek, B., Katalinic, A., Birgisson, H., Murray, D., Walsh, P. M., Mazzoleni, G., Vittadello, F., Cuccaro, F., Galasso, R., Sampietro, G., Rosso, S., Magoni, M., Ferrante, M., Sardo, A. S., Gambino, M. L., Ballotari, P., Giacomazzi, E., Ferretti, S., Caldarella, A., Manneschi, G., Gatta, G., Baili, P., Berrino, F., Botta, L., Trama, A., Lillini, R., Bernasconi, A., Bonfarnuzzo, S., Didone, F., Lasalvia, P., Del Monego, G., Magri, M. C., Buratti, L., Serraino, D., Dal Maso, L., Capocaccia, R., Demuru, E., Di Benedetto, C., Santaquilani, M., Venanzi, S., Filiberti, R. A., Iacovacci, S., Gennaro, V., Russo, A. G., Spagnoli, G., D'Oro, L. C., Fusco, M., Vitale, M. F., Usala, M., Vitale, F., Michiara, M., Chiranda, G., Cascone, G., Spata, E., Mangone, L., Falcini, F., Cavallo, R., Piras, D., Madeddu, A., Bella, F., Fanetti, A. C., Minerba, S., Candela, G., Scuderi, T., Rizzello, R. V., Stracci, F., Tagliabue, G., Rugge, M., Brustolin, A., Pildava, S., Smailyte, G., Azzopardi, M., Johannesen, T. B., Didkowska, J., Wojciechowska, U., Bielska-Lasota, M., Pais, A., Pontes, J. L., Miranda, A., Diba, C. S., Zadnik, V., Zagar, T., Escudero, C. S. -C., Sureda, P. F., de Munain, A. L., De-La-cruz, M., Rojas, M. D., Aleman, A., Vizcaino, A., Sanchez, M. J., Chirlaque, M. D., Eslava, M. G., Ardanaz, E., Galceran, J., Carulla, M., Bergeron, Y., Bouchardy, C., Mousavi, S. M., Bordoni, A., Visser, O., Rashbass, J., Gavin, A., Morrison, D., and Huws, D. W.

Subjects
Cancer Research, Survival, real-world data, randomized controlled trials (RCTs), tyrosine kinase inhibitor (TKI), population-based studies, Tyrosine kinase inhibitor (TKI), Randomized controlled trials (RCTs), survival, Real-world data, Europe, Oncology, cancer registries, chronic myeloid leukemia (CML), Chronic myeloid leukemia (CML), Cancer registries, Population-based studies
Abstract

This study was funded by the Compagnia di San Paolo, the Cariplo Foundation and the European Commission (grant number 801520 HP-JA-2017, Innovative Partnership for Action Against Cancer, iPAAC Joint Action). The sources of the funding played no role in designing the study, collecting, analyzing, or interpreting the data, writing the report, or deciding whether or not to submit the article for publication. This research was (partially) funded by Italian Ministry of Health "Ricerca Corrente" funds. Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This raises questions on the added value of results from population-based studies, which use real-world data, compared to results of randomized controlled trials (RCTs) involving patients with CML. There are also questions about the extent of the findings on RCTs effectiveness for patients in the general population. We compare survival data extracted from our previous systematic review and meta-analysis of CML RCTs with the latest updated population-based survival data of EUROCARE-6, the widest collaborative study on cancer survival in Europe. The EUROCARE-6 CML survival estimated in patients (15-64 years) diagnosed in 2000-2006 vs. 2007-2013 revealed that the prognostic improvement highlighted by RCTs was confirmed in real-world settings, too. The study shows, evaluating for the first time all European regions, that the optimal outcome figures obtained in controlled settings for CML are also achievable (and indeed achieved) in real-world settings with prompt introduction of TKIs in daily clinical practice. However, some differences still persist, particularly in Eastern European countries, where overall survival values are lower than elsewhere, probably due to a delayed introduction of TKIs. Our results suggest an insufficient adoption of adequate protocols in daily clinical practice in those countries where CML survival values remain lower in real life than the values obtained in RCTs. New high-resolution population-based studies may help to identify failures in the clinical pathways followed there.

Published
2022
Full Text
View/download PDF

16. Decline in the incidence of colorectal cancer and the associated mortality in young Italian adults

Author

Zorzi M., Cavestro G. M., Guzzinati S., Dal Maso L., Rugge M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R. A., Vitarelli S., Russo A. G., Carrozzi G., D'Orsi G., Fusco M., Sini G. M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A. L., Cesaraccio R., Madeddu A., Fanetti A. C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Tolin M., Brustolin A., Castelli M., Zorzi M., Cavestro G.M., Guzzinati S., Dal Maso L., Rugge M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R.A., Vitarelli S., Russo A.G., Carrozzi G., D'Orsi G., Fusco M., Sini G.M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A.L., Cesaraccio R., Madeddu A., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Tolin M., Brustolin A., Castelli M., Zorzi, M., Cavestro, G. M., Guzzinati, S., Dal Maso, L., and Rugge, M

Subjects
0301 basic medicine, Colon, Population, Socio-culturale, colorectal cancer, colorectal cancer screening, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Epidemiology of cancer, Medicine, Humans, Risk factor, education, education.field_of_study, cancer epidemiology, Colorectal cancer, colorectal cancer screening, business.industry, Incidence (epidemiology), Mortality rate, screening, Incidence, Gastroenterology, Cancer, medicine.disease, Obesity, Annual Percent Change, Europe, 030104 developmental biology, Italy, 030211 gastroenterology & hepatology, epidemiology, business, Colorectal Neoplasms, Demography, cancer epidemiology, SEER Program
Abstract

Objective The incidence of colorectal cancer (CRC) declines among subjects aged 50 years and above. An opposite trend appears among younger adults. In Europe, data on CRC incidence among younger adults are lacking. We therefore aimed to analyse European trends in CRC incidence and mortality in subjects younger than 50 years. Design Data on age-related CRC incidence and mortality between 1990 and 2016 were retrieved from national and regional cancer registries. Trends were analysed by Joinpoint regression and expressed as annual percent change. Results We retrieved data on 143.7 million people aged 20–49 years from 20 European countries. Of them, 187 918 (0.13%) were diagnosed with CRC. On average, CRC incidence increased with 7.9% per year among subjects aged 20–29 years from 2004 to 2016. The increase in the age group of 30–39 years was 4.9% per year from 2005 to 2016, the increase in the age group of 40–49 years was 1.6% per year from 2004 to 2016. This increase started earliest in subjects aged 20–29 years, and 10–20 years later in those aged 30–39 and 40–49 years. This is consistent with an age-cohort phenomenon. Although in most European countries the CRC incidence had risen, some heterogeneity was found between countries. CRC mortality did not significantly change among the youngest adults, but decreased with 1.1%per year between 1990 and 2016 and 2.4% per year between 1990 and 2009 among those aged 30–39 years and 40–49 years, respectively. Conclusion CRC incidence rises among young adults in Europe. The cause for this trend needs to be elucidated. Clinicians should be aware of this trend. If the trend continues, screening guidelines may need to be reconsidered.

Published
2020

17. A 3‐year interval is too short for re‐screening women testing negative for human papillomavirus: a population‐based cohort study

Author

Zorzi, M, Frayle, H, Rizzi, M, Fedato, C, Rugge, M, Penon, MG, Bertazzo, A, Callegaro, S, Campagnolo, M, Ortu, F, Del Mistro, A, Baracco, Susanna, Baboci, Lorena, Amadori, Alberto, Montaguti, Adriana, Turrin, Anna, Farruggio, Angelo, Cocco, Patrizia, Tumaini, Lucio, Gerace, Pierfrancesco, Borgato, Loretta, Maso, Renata, Bo, Patrizio, Mari, Lucia, Franzoi, Roberto, and Ferro, Antonio

Published
2017
Full Text
View/download PDF

18. P301 Non-familial small bowel carcinomas in Crohnʼs disease: clinico-pathological, molecular and prognostic features

Author

Di Sabatino, A., Vanoli, A., Furlan, D., Giuffrida, P., Klersy, C., Grillo, F., Fiocca, R., Mescoli, C., Rugge, M., Nesi, G., Fociani, P., Sampietro, G., Ardizzone, S., Luinetti, O., Calabrò, A., Tonelli, F., Volta, U., Santini, D., Caio, G., Elli, L., Ferrero, S., Latella, G., Ciardi, A., Solina, G., Rizzo, A., Ciacci, C., DʼArmiento, F.P., Salemme, M., Villanacci, V., Cannizzaro, R., Canzonieri, V., Reggiani Bonetti, L., Biancone, L., Monteleone, G., Orlandi, A., Santeusanio, G., Macciomei, M.C., DʼIncà, R., Perfetti, V., Sandri, G., Silano, M., Florena, A.M., Giannone, A.G., Papi, C., Coppola, L., Usai, P., Maccioni, A., Astegiano, M., Migliora, P., Manca, R., Martino, M., Trapani, D., Cerutti, R., Alberizzi, P., Riboni, R., Sessa, F., Paulli, M., Solcia, E., and Corazza, G.R.

Published
2017
Full Text
View/download PDF

20. Synthetic indicator of the impact of colorectal cancer screening programmes on incidence rates

Author

Zorzi M., Zappa M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R. A., Vitarelli S., Russo A. G., Carrozzi G., D'Orsi G., Fusco M., Sini G. M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A. L., Cesaraccio R., Madeddu A., Fanetti A. C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Rugge M., Brustolin A., Castelli M., Zorzi M., Zappa M., Mazzoleni G., Morrone G., Caputo E., Galasso R., Citarella A., Sampietro G., Magoni M., Cavalieri D'Oro L., Ardizzone A., D'Argenzio A., Sciacca S., Pisani S., Ricci P., Giorno A., Ferretti S., Palma F., Serraino D., Iacovacci S., Quarta F., Filiberti R.A., Vitarelli S., Russo A.G., Carrozzi G., D'Orsi G., Fusco M., Sini G.M., Vitale F., Michiara M., Boschetti L., Chiaranda G., Rosso S., Tumino R., Mangone L., Valenti Clemente S., Falcini F., Caiazzo A.L., Cesaraccio R., Madeddu A., Fanetti A.C., Minerba S., Caldarella A., Candela G., Piffer S., Stracci F., Tagliabue G., Rugge M., Brustolin A., and Castelli M.

Subjects
Adenoma, Male, Colorectal cancer, colorectal cancer, Target population, colorectal cancer screening, NO, Screening programme, Single indicator, medicine, Humans, Mass Screening, National level, Early Detection of Cancer, Aged, Potential impact, business.industry, Incidence, Incidence (epidemiology), Gastroenterology, Colonoscopy, Colorectal Neoplasms, Female, Italy, Middle Aged, Occult Blood, Patient Compliance, Program Evaluation, medicine.disease, Colorectal cancer screening, business, Demography
Abstract

ObjectiveThe impact of a screening programme on colorectal cancer (CRC) incidence in its target population depends on several variables, including coverage with invitations, participation rate, positivity rate of the screening test, compliance with an invitation to second-level assessment and endoscopists’ sensitivity. We propose a synthetic indicator that may account for all the variables influencing the potential impact of a screening programme on CRC incidence.DesignWe defined the ‘rate of advanced adenoma on the target population’ (AA-TAP) as the rate of patients who received a diagnosis of advanced adenoma within a screening programme, divided by the programme target population. We computed the AA-TAP for the CRC Italian screening programmes (biennial faecal immunochemical test, target population 50–69 year olds) using the data of the Italian National Survey from 2003 to 2016, overall and by region, and assessed the association between AA-TAP and CRC incidence fitting a linear regression between the trend of regional CRC incidence rates in 50–74 year old subjects and the cumulative AA-TAP.ResultsIn 2016, the AA-TAP at a national level was 105×100 000, whereas significant differences were observed between the northern and central regions (respectively 126 and 149×100 000) and the South and Islands (36×100 000). The cumulative AA-TAP from 2004 to 2012 was significantly correlated with the difference between CRC incidence rates in 2013–2014 and those in 2003–2004 (p=0.009).ConclusionThe AA-TAP summarises into a single indicator the potential impact of a screening programme in reducing CRC incidence rates.

Published
2019
Full Text
View/download PDF

22. Changes in life expectancy for cancer patients over time since diagnosis

Author

Botta, L., Dal Maso, L., Guzzinati, S., Panato, C., Gatta, G., Trama, A., Rugge, M., Tagliabue, G., Casella, C., Caruso, B., Michiara, M., Ferretti, S., Sensi, F., Tumino, R., Toffolutti, F., Russo, A. G., Caiazzo, A. L., Mangone, L., Mazzucco, W., Iacovacci, S., Ricci, P., Gola, G., Candela, G., Sardo, A. S., De Angelis, R., Buzzoni, C., Capocaccia, R., AIRTUM Working Group, Botta, Laura, Dal Maso, Luigino, Guzzinati, Stefano, Panato, Chiara, Gatta, Gemma, Trama, Annalisa, Rugge, Massimo, Tagliabue, Giovanna, Casella, Claudia, Caruso, Bianca, Michiara, Maria, Ferretti, Stefano, Sensi, Flavio, Tumino, Rosario, Toffolutti, Federica, Giampiero Russo, Antonio, Luisa Caiazzo, Anna, Mangone, Lucia, Mazzucco, Walter, Iacovacci, Silvia, Ricci, Paolo, Gola, Gemma, Candela, Giuseppa, Sutera Sardo, Antonella, De Angelis, Roberta, Buzzoni, Carlotta, and Capocaccia, Riccardo

Subjects
0301 basic medicine, Pediatrics, medicine.medical_specialty, cancer survivor, Life expectancy, Cancer survivors, Population, YLL, years of life lost, (ICD-O-3), international classification of diseases for oncology, third revision, Socio-culturale, Life expectancy, Population-based cancer registry, Relative survival, Cancer, Cancer survivors, Italy, Settore MED/42 - Igiene Generale E Applicata, Relative survival, 03 medical and health sciences, 0302 clinical medicine, Health care, Medicine, education, lcsh:Science (General), Population-based cancer registry, Thyroid cancer, Cancer, RS, relative survival, education.field_of_study, lcsh:R5-920, Multidisciplinary, business.industry, Absolute risk reduction, medicine.disease, LE, life expectancy, NHL, non-Hodgkin lymphoma, 030104 developmental biology, Years of potential life lost, Italy, ISTAT, national institute of statistics, 030220 oncology & carcinogenesis, (ICD-10), international classification of diseases tenth revision, Original Article, business, lcsh:Medicine (General), lcsh:Q1-390
Abstract

Highlights • Research question: how cancer impacts on LE changes during patients’ entire life • LE increased in patients surviving the first years and decreasing thereafter. • Patients’ LE in the end approached but seldom reached the general population’s LE. • This method describes when cancer survivors’ excess risk of death became negligible. • Life expectancy indicator is easy to be understood and interpreted by patients., Graphical abstract, The aims of this study were to provide life expectancy (LE) estimates of cancer patients at diagnosis and LE changes over time since diagnosis to describe the impact of cancer during patients' entire lives. Cancer patients' LE was calculated by standard period life table methodology using the relative survival of Italian patients diagnosed in population-based cancer registries in 1985–2011 with follow-up to 2013. Data were smoothed using a polynomial model and years of life lost (YLL) were calculated as the difference between patients' LE and that of the age- and sex-matched general population. The YLL at diagnosis was highest at the youngest age at diagnosis, steadily decreasing thereafter. For patients diagnosed at age 45 years, the YLL was above 20 for lung and ovarian cancers and below 6 for thyroid cancer in women and melanoma in men. LE progressively increased in patients surviving the first years, decreasing thereafter, to approach that of the general population. YLL in the long run mainly depends on attained age. Providing quantitative data is essential to better define clinical follow-up and plan health care resource allocation. These results help assess when the excess risk of death from tumour becomes negligible in cancer survivors.

Published
2019

23. The stomach in health and disease

Author

Hunt, R H, Camilleri, M, Crowe, S E, El-Omar, E M, Fox, J G, Kuipers, E J, Malfertheiner, P, McColl, K E L, Pritchard, D M, Rugge, M, Sonnenberg, A, Sugano, K, and Tack, J

Published
2015
Full Text
View/download PDF

26. Diagnosis of digestive system tumours

Author

Washington, M.K., Goldberg, R.M., Chang, G.J., Limburg, P., Lam, A.K., Salto-Tellez, M., Arends, M.J., Nagtegaal, I.D., Klimstra, D.S., Rugge, M., Schirmacher, P., Lazar, A.J., Odze, R.D., Carneiro, F., Fukayama, M., Cree, I.A., Washington, M.K., Goldberg, R.M., Chang, G.J., Limburg, P., Lam, A.K., Salto-Tellez, M., Arends, M.J., Nagtegaal, I.D., Klimstra, D.S., Rugge, M., Schirmacher, P., Lazar, A.J., Odze, R.D., Carneiro, F., Fukayama, M., and Cree, I.A.

Abstract

Item does not contain fulltext, The WHO Classification of Tumours provides the international standards for the classification and diagnosis of tumours. It enables direct comparisons to be made between different countries. In the new fifth edition, the series has gone digital with the launch of a website as well as a series of books, known widely as the WHO Blue Books. The first volume to be produced is on the classification of Digestive System tumours, replacing the successful 2010 version. It has been rewritten and updated accordingly. This article summarises the major diagnostic innovations that have occurred over the last decade and that have now been incorporated in the classification. As an example, it incorporates the recently proposed classification of neuroendocrine tumours, based on the recognition that neuroendocrine tumours and carcinomas differ substantially in the genetic abnormalities that drive their growth, findings relevant to treatment selection and outcome prediction. Several themes have emerged during the production process. One is the importance of the progression from hyperplasia to dysplasia to carcinoma in the evolution of the malignant process. Advances in imaging techniques and endoscopy have resulted in enhanced access to precancerous lesions in the gastrointestinal and biliary tract, necessitating both changes in classification schema and clinical practice. Diagnosis of tumours is no longer the sole purview of pathologists, and some patients now receive treatment before tissue is obtained, based on clinical, radiological and liquid biopsy results. This makes the classification relevant to many disciplines involved in the care of patients with tumours of the digestive system.

Published
2021

28. OLGA staging for gastritis: A tutorial

Author

Rugge, M., Correa, P., Di Mario, F., El-Omar, E., Fiocca, R., Geboes, K., Genta, R.M., Graham, D.Y., Hattori, T., Malfertheiner, P., Nakajima, S., Sipponen, P., Sung, J., Weinstein, W., and Vieth, M.

Published
2008
Full Text
View/download PDF

29. Prognosis and cure of long-term cancer survivors: A population-based estimation

Author

Dal Maso, L., Panato, C., Guzzinati, S., Serraino, D., Francisci, S., Botta, L., Capocaccia, R., Tavilla, A., Gigli, A., Crocetti, E., Rugge, M., Tagliabue, G., Filiberti, R. A., Carrozzi, G., Michiara, M., Ferretti, S., Cesaraccio, R., Tumino, R., Falcini, F., Stracci, F., Torrisi, A., Mazzoleni, G., Fusco, M., Rosso, S., Tisano, F., Fanetti, A. C., Sini, G. M., Buzzoni, C., De Angelis, R., Virdone, S., Gatta, G., Zorzi, M., Mallone, S., Toffolutti, F., Russo, A. G., Caiazzo, A. L., Mangone, L., Mazzucco, W., Pannozzo, F., Ricci, P., Gola, G., Candela, G., Sutera Sardo, A., Dal Maso L., Panato C., Guzzinati S., Serraino D., Francisci S., Botta L., Capocaccia R., Tavilla A., Gigli A., Crocetti E., Rugge M., Tagliabue G., Filiberti R.A., Carrozzi G., Michiara M., Ferretti S., Cesaraccio R., Tumino R., Falcini F., Stracci F., Torrisi A., Mazzoleni G., Fusco M., Rosso S., Tisano F., Fanetti A.C., Sini G.M., Buzzoni C., De Angelis R., Virdone S., Gatta G., Zorzi M., Mallone S., Toffolutti F., Russo A.G., Caiazzo A.L., Mangone L., Mazzucco W., Pannozzo F., Ricci P., Gola G., Candela G., and Sutera Sardo A.

Subjects
0301 basic medicine, Oncology, Male, Cancer Research, Time Factors, Settore MED/42 - Igiene Generale E Applicata, 0302 clinical medicine, Cancer Survivors, Prostate, Neoplasms, Thyroid cancer, Original Research, education.field_of_study, Relative survival, Mortality rate, Middle Aged, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Prognosis, population-based cancer registrie, medicine.anatomical_structure, Italy, 030220 oncology & carcinogenesis, cancer cure, Italy, population-based cancer registries, prevalence, survival, Female, Cancer Prevention, Adult, medicine.medical_specialty, population-based cancer registries, Adolescent, Population, prevalence, Socio-culturale, lcsh:RC254-282, survival, 03 medical and health sciences, Young Adult, Life Expectancy, Internal medicine, medicine, population‐based cancer registries, Humans, Radiology, Nuclear Medicine and imaging, cancer cure, education, Aged, Estimation, business.industry, Cancer, Models, Theoretical, medicine.disease, 030104 developmental biology, Life expectancy, business
Abstract

Background: Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population-based indicators of cancer cure. Methods: Information on more than half a million cancer patients aged 15-74 years collected by population-based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5-year conditional relative survival (CRS) >90% or 95% (time to cure). Results: Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was 95% was 90% was reached in 15 years. Conclusions: The study findings confirmed that several cancer types are curable. The awareness of the possibility of cancer cure has relevant clinical and social impacts. KEYWORDS cancer cure, Italy, population-based cancer registries, prevalence, survival

Published
2019
Full Text
View/download PDF

32. Allelic Imbalance Analysis in Liquid Biopsy to Monitor Locally Advanced Esophageal Cancer Patients During Treatment

Author

Boldrin, E., Curtarello, M., Fassan, M., Rugge, M., Realdon, S., Alfieri, R., Amadori, A., and Saggioro, D.

Subjects
allelic imbalance, circulating cell free DNA (cfDNA), esophageal adenocarcinoma (EADC), esophageal cancer, esophageal squamous cell carcinoma (ESCC), liquid biopsy, longitudinal studies, loss of heterozygosis (LOH), Cancer Research, Oncology, Original Research
Abstract

Esophageal cancer (EC) is a highly aggressive tumor, and the current monitoring procedures are partially inadequate to evaluate treatment efficacy. The aim of this study was to investigate whether allelic imbalance analysis in liquid biopsy could be used as an additional tool to monitor tumor burden in EC patients. For this purpose, circulating cell-free DNA (cfDNA) from 52 patients with a locally advanced EC, which underwent neoadjuvant treatment and resection, was analyzed. Data from four representative longitudinally followed patients are also reported. Furthermore, 17 DNAs from formalin-fixed paraffin-embedded (FFPE) tumor samples were analyzed and compared to time-matched cfDNAs. To look for allelic imbalance, which is the main genetic alteration in both EC histotypes, we used a panel of five microsatellites (MSs) and three single-nucleotide polymorphisms (SNPs) near genes described as frequently altered. The Fisher exact and Mann-Whitney U tests were used to analyze categorical and continuous data, respectively. The correlation coefficient between cfDNA and FFPE-DNA was calculated with the Pearson's correlation test. We found that the selected tumor-related alterations are present in cfDNA of both adenocarcinoma (EADC) and squamous cell carcinoma (ESCC) with similar frequencies. The only exception were the MSs, one downstream and one upstream, of SMAD4 of which the loss was only observed in EADC (26 vs. 0%, P = 0.018). More interestingly, longitudinal studies disclosed that in patients with disease progression, tumor-related alterations were present in cfDNA before overt clinical or instrumental signs of relapse. In conclusion, our data indicate that the evaluation of tumor-related gene allelic imbalance in cfDNA might be a useful tool to complement the current monitoring procedures for EC patients and to guide their management.

Published
2020

33. Gastrointestinal tissue‐based molecular biomarkers: A practical categorization based on the 2019 WHO Classification of Epithelial Digestive Tumours

Author

Quezada‐marín, J., Lam, Ak., Ochiai, A., Odze, R., Washington, Mk., Fukuyama, M., Rugge, M., Kimstra, Ds., Nagtegaal, Id., Tan, Ph., Arends, Mark J, Goldblum, Jr., Cree, Ia., and Salto‐tellez, M.

Subjects
WHO, Gastro intestinal Neoplasms, Genomics, Molecular Pathology, Biomarkers
Abstract

Molecular biomarkers have become one of the cornerstones of oncological pathology. The method of classification not only directly affects the manner in which patients are diagnosed and treated, but also guide the development of drugs and of artificial intelligence tools. This work aims to organize and update gastrointestinal molecular biomarkers in order to produce an easy-to-use guide for routine diagnostics. For this purpose, we have extracted and re-organized the molecular information of epithelial neoplasms included in the new “WHO Classification of Tumours of the Digestive System” book (5th Edition 2019).

Published
2020
Full Text
View/download PDF

34. Correction: PD-L1 in small bowel adenocarcinoma is associated with etiology and tumor-infiltrating lymphocytes, in addition to microsatellite instability (Modern Pathology, (2020), 33, 7, (1398-1409), 10.1038/s41379-020-0497-0)

Author

Giuffrida, P., Arpa, G., Grillo, F., Klersy, C., Sampietro, G., Ardizzone, S., Fociani, P., Fiocca, R., Latella, G., Sessa, F., D'Errico, A., Malvi, D., Mescoli, C., Rugge, M., Nesi, G., Ferrero, S., Furlan, D., Poggioli, G., Rizzello, F., Macciomei, M. C., Santini, D., Volta, U., De Giorgio, R., Caio, G., Calabro, A., Ciacci, C., D'Armiento, M., Rizzo, A., Solina, G., Martino, M., Tonelli, F., Villanacci, V., Cannizzaro, R., Canzonieri, V., Florena, A. M., Biancone, L., Monteleone, G., Caronna, R., Ciardi, A., Elli, L., Caprioli, F., Vecchi, M., D'Inca, R., Zingone, F., D'Odorico, A., Lenti, M. V., Oreggia, B., Bonetti, L. R., Astegiano, M., Biletta, E., Cantoro, L., Giannone, A. G., Orlandi, A., Papi, C., Perfetti, V., Quaquarini, E., Sandri, G., Silano, M., Usai, P., Barresi, V., Ciccocioppo, R., Luinetti, O., Pedrazzoli, P., Pietrabissa, A., Viglio, A., Paulli, M., Corazza, G. R., Solcia, E., Vanoli, A., and Di Sabatino, A.

Published
2020

36. Liver repopulation with bone marrow derived cells improves the metabolic disorder in the Gunn rat

Author

Muraca, M., Ferraresso, C., Vilei, M.T., Granato, A., Quarta, M., Cozzi, E., Rugge, M., Pauwelyn, K.A., Caruso, M., Avital, I., Inderbitzin, D., Demetriou, A.A., Forbes, S.J., and Realdi, G.

Subjects
Hyperbilirubinemia -- Care and treatment, B cells -- Physiological aspects, Rats as laboratory animals -- Physiological aspects, Rats as laboratory animals -- Research, Bone marrow -- Transplantation, Bone marrow -- Patient outcomes, Bone marrow -- Research, Health
Published
2007

37. Gastrointestinal tissue-based molecular biomarkers: a practical categorisation based on the 2019 World Health Organization classification of epithelial digestive tumours

Author

Quezada-Marín, J.I., Lam, A.K., Ochiai, A., Odze, R.D., Washington, K.M., Fukayama, M., Rugge, M., Klimstra, D.S., Nagtegaal, I.D., Tan, P.H., Arends, M.J., Goldblum, J.R., Cree, I.A., Salto-Tellez, M., Quezada-Marín, J.I., Lam, A.K., Ochiai, A., Odze, R.D., Washington, K.M., Fukayama, M., Rugge, M., Klimstra, D.S., Nagtegaal, I.D., Tan, P.H., Arends, M.J., Goldblum, J.R., Cree, I.A., and Salto-Tellez, M.

Abstract

Contains fulltext : 225959pub.pdf (publisher's version ) (Open Access), Molecular biomarkers have come to constitute one of the cornerstones of oncological pathology. The method of classification not only directly affects the manner in which patients are diagnosed and treated, but also guides the development of drugs and of artificial intelligence tools. The aim of this article is to organise and update gastrointestinal molecular biomarkers in order to produce an easy-to-use guide for routine diagnostics. For this purpose, we have extracted and reorganised the molecular information on epithelial neoplasms included in the 2019 World Health Organization classification of tumours. Digestive system tumours, 5th edn.

Published
2020

38. The 2019 WHO classification of tumours of the digestive system

Author

Nagtegaal, I.D., Odze, R.D., Klimstra, D.S., Paradis, V., Rugge, M., Schirmacher, P., Washington, K.M., Carneiro, F., Cree, I.A., Nagtegaal, I.D., Odze, R.D., Klimstra, D.S., Paradis, V., Rugge, M., Schirmacher, P., Washington, K.M., Carneiro, F., and Cree, I.A.

Abstract

Contains fulltext : 229796.pdf (Publisher’s version ) (Open Access)

Published
2020

39. Autoimmune gastritis.

Author

Lenti M.V., Di Sabatino A., Hershko C., De Block C., Genta R.M., Toh B.-H., Miceli E., Lahner E., Rugge M., Lenti M.V., Di Sabatino A., Hershko C., De Block C., Genta R.M., Toh B.-H., Miceli E., Lahner E., and Rugge M.

Abstract

Autoimmune gastritis (AIG) is an increasingly prevalent, organ-specific, immune-mediated disorder characterized by the destruction of gastric parietal cells, leading to the loss of intrinsic factor and reduced acid output. These alterations result in malabsorption of iron, vitamin B12 (pernicious anaemia) and potentially other micronutrients. For several years, most studies have focused on pernicious anaemia only, generating confusion between the two entities. In AIG, the gastric proton pump, H+/K+ ATPase, is the major autoantigen recognized by autoreactive T cells. The T cell-dependent activation of B cells stimulates the production of anti-parietal cell antibodies, the serological hallmark of AIG. The role of Helicobacter pylori infection in activating or favouring the autoimmune process is still uncertain. Early histopathological alterations allowing a more precise and prompt recognition have recently been described. AIG is burdened by a substantial diagnostic delay as it can present with varied clinical signs including, among others, gastrointestinal symptoms and neuropsychiatric manifestations. In advanced stages, AIG might progress to neuroendocrine tumours and gastric adenocarcinoma. Management includes early detection through a proactive case-finding strategy, micronutrient supplementation and endoscopic surveillance. This Primer comprehensively describes the most important insights regarding the epidemiology, pathophysiology, diagnosis and management of AIG, focusing on the most controversial, outstanding issues and future directions.Copyright © 2020, Springer Nature Limited.

Published
2020

40. Ethics in clinical autopsy

Author

Rugge, M., Sacchi, D., Cesaro, S., Sbaraglia, M., Locatelli, Franco, Locatelli F. (ORCID:0000-0002-7976-3654), Rugge, M., Sacchi, D., Cesaro, S., Sbaraglia, M., Locatelli, Franco, and Locatelli F. (ORCID:0000-0002-7976-3654)

Abstract

This manuscript concerns the ethical aspects of the clinical autopsy procedure. Much of the literature on this topic addresses some of the multifaceted issues potentially involved: religious beliefs and/or cultural traditions coming to bear on the management of autopsies, relations between families and healthcare personnel (physicians and technicians) involved in conducting an autopsy, ethical implications of regulations to follow and procedures for obtaining biological samples for further diagnostics or research. All these issues have ethical implications, particularly in today's globalised cultural domain. To preserve for future generations the teaching and scientific value of the clinical autopsy, scientific societies and academic institutions should endorse educational efforts to promote the ethical management of autopsy procedures.

Published
2020

41. Use of an artificial neural network to identify patient clusters in a large cohort of patients with melanoma by simultaneous analysis of costs and clinical characteristics

Author

Damiani, G., Buja, A., Grossi, E., Rivera, M., DE POLO, A., DE LUCA, G., Zorzi, M., Vecchiato, A., Del Fiore, P., Saia, M., Baldo, V., Rugge, M., Rossi, C. R., Damiani, Gianfranco, Damiani G. (ORCID:0000-0003-3028-6188), Damiani, G., Buja, A., Grossi, E., Rivera, M., DE POLO, A., DE LUCA, G., Zorzi, M., Vecchiato, A., Del Fiore, P., Saia, M., Baldo, V., Rugge, M., Rossi, C. R., Damiani, Gianfranco, and Damiani G. (ORCID:0000-0003-3028-6188)

Abstract

The incidence of cutaneous malignant melanoma (CMM) in Italy has increased in the last decade, leading to publichealth concern and rising costs of healthcare (1, 2). In addition to individual susceptibility to development of CMM, several environmental variables influence prognosis in this disease. These variables include social disparities, socioeconomic status, education and marital status (3). How ever, the impact of these variables on costs is unknown. The current study used a new methodology, based on an artificial neural network (ANN), to decodify this complexity by simultaneously describing the relation-ships between clinical, sociodemographic, outcome, and cost variables, and grouping patients into clusters (4, 5).

Published
2020

42. The Veneto Region's Barrett's Oesophagus Registry: Aims, methods, preliminary results

Author

Zaninotto, G., Minnei, F., Guirroli, E., Ceolin, M., Battaglia, G., Bellumat, A., Betetto, G., Bozzola, L., Cassaro, M., Cataudella, G., Dal Bò, N., Farinati, F., Florea, G., Furlanetto, A., Galliani, E., Germanà, B., Guerini, A., Macrì, E., Marcon, V., Mastropaolo, G., Meggio, A., Miori, G., Morelli, L., Murer, B., Norberto, L., Togni, R., Valiante, F., and Rugge, M.

Published
2007
Full Text
View/download PDF

49. The long term outcome of gastric non-invasive neoplasia

Author

Rugge, M, Cassaro, M, Di Mario, F, Leo, G, Leandro, G, Russo, VM, Pennelli, G, and Farinati, F

Subjects
Dysplasia -- Influence -- Diagnosis -- Risk factors, Cancer -- Diagnosis -- Risk factors, Stomach cancer -- Risk factors -- Diagnosis, Statistics, Health, Influence, Diagnosis, Risk factors
Abstract

Background: The cancer risk associated with gastric non-invasive neoplasia (formerly dysplasia) is debated. This prospective long term follow up study investigates the clinicopathological behaviour of non-invasive gastric neoplasia (and related [...]

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results